Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Reuters Investment Profile
Provider: S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals Inc issues Q4 2013 revenue guidance in line with analysts' estimates-conference call

Tuesday, 5 Nov 2013 04:30pm EST 

Isis Pharmaceuticals Inc:Expects Q4 2013 revenue in the mid $30 mln range, including revenue from the amortization of up-front fees of about $15 mln, which includes the new revenue from fourth Biogen Idec collaboration.Q4 2013 revenue of $36 mln - Thomson Reuters I/B/E/S. 

Company Quote

21 Nov 2014